التفاصيل البيبلوغرافية
| العنوان: |
Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients. |
| المؤلفون: |
Antelo, M. Luisa1 (AUTHOR) manteloc@cfnavarra.es, Altuna, Ane2 (AUTHOR) ane.altunamonguelos@osakidetza.eus, Gimeno, J. José3 (AUTHOR) jjgimeno@saludaragon.es, Ferreiro, J. Javier2 (AUTHOR) josejavier.ferreiromartinez@osakidetza.eus, Amunárriz, Cristina4 (AUTHOR) crisamu@bscan.org, Mateos, J. José5 (AUTHOR) juanjose.mateosmazon@osakidetza.eus, Zalba, Saioa1 (AUTHOR) saoia.zalba.marcos@navarra.es, Alkorta, Aitziber2 (AUTHOR) aitziber.alkortaeizagirre@osakidetza.eus, Rifón, José6 (AUTHOR) jrifon@unav.es, Arroyo, J. Luis4 (AUTHOR) director@bscan.org, Uresandi, Amaia5 (AUTHOR) amaia.uresandi@osakidetza.eus, Moreno, J. Antonio7 (AUTHOR) jamoreno@salud.aragon.es, Nájera, M. Josefa8 (AUTHOR) mjnajera@riojasalud.es, Pinzón, Sergio3 (AUTHOR) spinzon48@gmail.com, García, Alejandro3 (AUTHOR) alex_ortego@hotmail.com, Vallejo, J. Carlos2 (AUTHOR) JUANCARLOS.VALLEJOLLAMAS@osakidetza.eus |
| المصدر: |
Transfusion & Apheresis Science. Jun2021, Vol. 60 Issue 3, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*STEM cell transplantation, *HEMATOPOIETIC stem cell transplantation, *PLATELET count |
| مستخلص: |
• Plerixafor (PLX) enhances hematopoietic stem-cell mobilization for transplantation. • Data on the quality of engraftment after mobilization with PLX is presented. • In a large series, PLX allowed transplantation of 86 % poorly mobilized patients. • Optimal engraftment was generally evident 100 days after transplantation. • Engraftment efficiency was optimal for different causes of mobilization failure. Plerixafor (PLX) appears to effectively enhance hematopoietic stem-cell mobilization prior to autologous hematopoietic stem cell transplantation (auto-HCT). However, the quality of engraftment following auto-HCT has been little explored. Here, engraftment following auto-HCT was assessed in patients mobilized with PLX through a retrospective, multicenter study of 285 consecutive patients. Information on early and 100-day post-transplant engraftment was gathered from the 245 patients that underwent auto-HCT. The median number of PLX days to reach the stem cell collection goal (≥2 × 106 CD34+ cells/kg) was 1 (range 1–4) and the median PLX administration time before apheresis was 11 h (range 1–18). The median number of apheresis sessions to achieve the collection goal was 2 (range 1–5) and the mean number of CD34+ cells collected was 2.95 × 106/kg (range 0–30.5). PLX administration was safe, with only 2 mild and transient gastrointestinal adverse events reported. The median time to achieve an absolute neutrophil count (ANC) >500/μL was 11 days (range 3–31) and the median time to platelet recovery >20 × 103/μL was 13 days (range 5–69). At 100 days after auto-HCT, the platelet count was 137 × 109/L (range 7–340), the ANC was 2.3 × 109/L (range 0.1–13.0), and the hemoglobin concentration was 123 g/L (range 79–165). PLX use allowed auto-HCT to be performed in a high percentage of poorly mobilized patients, resulting in optimal medium-term engraftment in the majority of patients in whom mobilization failed, in this case mainly due to suboptimal peripheral blood CD34+ cell concentration on day +4 or low CD34+ cell yield on apheresis. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
